Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dennis Christoph Harrer

Showing results (1-10 of 28) with videos related to

Pageof 3
Sort By:
International Journal of Molecular Sciences|February 11, 2023
CARs and Drugs: Pharmacological Ways of Boosting CAR-T-Cell TherapyDennis Christoph Harrer, Jan Dörrie, Niels Schaft
International Journal of Molecular Sciences|January 28, 2026
Genome Agnostic Reprogramming of Acute Myelocytic Leukemia Hallmarks by Targeting Non-Oncogene Addictions with Azacitidine Plus Pioglitazone and All-Trans Retinoic AcidDennis Christoph Harrer, Florian Lüke, Tobias Pukrop, et al.
Frontiers in Immunology|June 8, 2023
IRF4 downregulation improves sensitivity and endurance of CAR T cell functional capacitiesDennis Christoph Harrer, Valerie Bezler, Jordan Hartley, et al.
Cancers|August 10, 2024
Ectopic PU.1 Expression Provides Chimeric Antigen Receptor (CAR) T Cells with Innate Cell Capacities Including IFN-β ReleaseDennis Christoph Harrer, Matthias Eder, Markus Barden, et al.
Cancers|January 11, 2024
Addressing Genetic Tumor Heterogeneity, Post-Therapy Metastatic Spread, Cancer Repopulation, and Development of Acquired Tumor Cell ResistanceDennis Christoph Harrer, Florian Lüke, Tobias Pukrop, et al.
Frontiers in Pharmacology|March 12, 2026
Genome agnostic, multi-level non-oncogene addiction-based systems pharmacology for rescuing metastatic relapsed/refractory neoplasiasDennis Christoph Harrer, Florian Lüke, Tobias Pukrop, et al.
Frontiers in Oncology|November 2, 2020
Unusual Late Relapse of ALK-Positive Anaplastic Large Cell Lymphoma Successfully Cleared Using the ALK-Inhibitor Crizotinib: Case ReportDennis Christoph Harrer, Karin Menhart, Stephanie Mayer, et al.
Frontiers in Pharmacology|April 4, 2025
MEPED as salvage therapy for relapsed/refractory Hodgkin's lymphoma incorporating edited non-oncogene addiction: mTOR as a bottleneckDennis Christoph Harrer, Florian Lüke, Tobias Pukrop, et al.
Frontiers in Immunology|December 13, 2023
Fine-tuning the antigen sensitivity of CAR T cells: emerging strategies and current challengesDennis Christoph Harrer, Sin-Syue Li, Marcell Kaljanac, et al.
Cancers|October 27, 2022
Decitabine-Mediated Upregulation of CSPG4 in Ovarian Carcinoma Cells Enables Targeting by CSPG4-Specific CAR-T CellsDennis Christoph Harrer, Charlotte Schenkel, Carola Berking, et al.
Pageof 3

Showing results (1-10 of 28) with videos related to

Sort By:
Pageof 3
International Journal of Molecular Sciences|February 11, 2023
CARs and Drugs: Pharmacological Ways of Boosting CAR-T-Cell TherapyDennis Christoph Harrer, Jan Dörrie, Niels Schaft
International Journal of Molecular Sciences|January 28, 2026
Genome Agnostic Reprogramming of Acute Myelocytic Leukemia Hallmarks by Targeting Non-Oncogene Addictions with Azacitidine Plus Pioglitazone and All-Trans Retinoic AcidDennis Christoph Harrer, Florian Lüke, Tobias Pukrop, et al.
Frontiers in Immunology|June 8, 2023
IRF4 downregulation improves sensitivity and endurance of CAR T cell functional capacitiesDennis Christoph Harrer, Valerie Bezler, Jordan Hartley, et al.
Cancers|August 10, 2024
Ectopic PU.1 Expression Provides Chimeric Antigen Receptor (CAR) T Cells with Innate Cell Capacities Including IFN-β ReleaseDennis Christoph Harrer, Matthias Eder, Markus Barden, et al.
Cancers|January 11, 2024
Addressing Genetic Tumor Heterogeneity, Post-Therapy Metastatic Spread, Cancer Repopulation, and Development of Acquired Tumor Cell ResistanceDennis Christoph Harrer, Florian Lüke, Tobias Pukrop, et al.
Frontiers in Pharmacology|March 12, 2026
Genome agnostic, multi-level non-oncogene addiction-based systems pharmacology for rescuing metastatic relapsed/refractory neoplasiasDennis Christoph Harrer, Florian Lüke, Tobias Pukrop, et al.
Frontiers in Oncology|November 2, 2020
Unusual Late Relapse of ALK-Positive Anaplastic Large Cell Lymphoma Successfully Cleared Using the ALK-Inhibitor Crizotinib: Case ReportDennis Christoph Harrer, Karin Menhart, Stephanie Mayer, et al.
Frontiers in Pharmacology|April 4, 2025
MEPED as salvage therapy for relapsed/refractory Hodgkin's lymphoma incorporating edited non-oncogene addiction: mTOR as a bottleneckDennis Christoph Harrer, Florian Lüke, Tobias Pukrop, et al.
Frontiers in Immunology|December 13, 2023
Fine-tuning the antigen sensitivity of CAR T cells: emerging strategies and current challengesDennis Christoph Harrer, Sin-Syue Li, Marcell Kaljanac, et al.
Cancers|October 27, 2022
Decitabine-Mediated Upregulation of CSPG4 in Ovarian Carcinoma Cells Enables Targeting by CSPG4-Specific CAR-T CellsDennis Christoph Harrer, Charlotte Schenkel, Carola Berking, et al.
Pageof 3